Cargando…

Efficacy of pegylated interferon α-2a and α-2b in patients with genotype 1 chronic hepatitis C: a meta-analysis

BACKGROUND: Two formulations of Pegylated interferon (Peg-IFN) are on the market for treatment of chronic hepatitis C virus (HCV) infection. The purpose of this meta-analysis was to assess the efficacy of Peg-IFN α-2a versus Peg-IFN α-2b in combination with ribavirin in anti-human immunodeficiency v...

Descripción completa

Detalles Bibliográficos
Autores principales:	Coppola, Nicola, Pisaturo, Mariantonietta, Tonziello, Gilda, Sagnelli, Caterina, Sagnelli, Evangelista, Angelillo, Italo F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3556138/ https://www.ncbi.nlm.nih.gov/pubmed/23245594 http://dx.doi.org/10.1186/1471-2334-12-357

Ejemplares similares

Peg-Interferon Plus Ribavirin with or without Boceprevir or Telaprevir for HCV Genotype 1: A Meta-Analysis on the Role of Response Predictors
por: Coppola, Nicola, et al.
Publicado: (2014)

Rituximab-Based Treatment, HCV Replication, and Hepatic Flares
por: Sagnelli, Evangelista, et al.
Publicado: (2012)

Hepatitis B virus/hepatitis D virus epidemiology: Changes over time and possible future influence of the SARS-CoV-2 pandemic
por: Sagnelli, Caterina, et al.
Publicado: (2021)

Liver microRNA hsa-miR-125a-5p in HBV Chronic Infection: Correlation with HBV Replication and Disease Progression
por: Coppola, Nicola, et al.
Publicado: (2013)

Reactivation of hepatitis B virus infection in patients with hemo-lymphoproliferative diseases, and its prevention
por: Sagnelli, Caterina, et al.
Publicado: (2019)

Epidemiology and management of hepatitis C virus infections in immigrant populations
por: Coppola, Nicola, et al.
Publicado: (2019)

HBV/HDV Co-Infection: Epidemiological and Clinical Changes, Recent Knowledge and Future Challenges
por: Sagnelli, Caterina, et al.
Publicado: (2021)

Association between anti-HBc positivity and hepatocellular carcinoma in HBsAg-negative subjects with chronic liver disease: A meta-analysis
por: Coppola, Nicola, et al.
Publicado: (2016)

Hepatitis B virus infection in undocumented immigrants and refugees in Southern Italy: demographic, virological, and clinical features
por: Coppola, Nicola, et al.
Publicado: (2017)

COVID-19 as Another Trigger for HBV Reactivation: Clinical Case and Review of Literature
por: Sagnelli, Caterina, et al.
Publicado: (2022)

SARS-CoV-2 infection: a hurricane that does not ignore chronic hepatitis
por: Sagnelli, Caterina, et al.
Publicado: (2022)

Micro-RNAs in hepatitis B virus-related chronic liver diseases and hepatocellular carcinoma
por: Sagnelli, Evangelista, et al.
Publicado: (2018)

Low prevalence of HTLV1/2 infection in a population of immigrants living in southern Italy
por: Alessio, Loredana, et al.
Publicado: (2018)

Characteristics and Changes over Time of Alcohol-Related Chronic Liver Diseases in Italy
por: Stroffolini, Tommaso, et al.
Publicado: (2018)

Anti-hepatitis C virus treatment may prevent the progression of liver fibrosis in non-responder human immunodeficiency virus/hepatitis C virus coinfected patients
por: Sagnelli, Caterina, et al.
Publicado: (2013)

Comparison of Compliance and Efficacy of Pegylated Interferon α-2a and α-2b in Adults with Chronic Hepatitis C
por: Hu, Jing-Hong, et al.
Publicado: (2019)

TM6SF2 E167K variant predicts severe liver fibrosis for human immunodeficiency/hepatitis C virus co-infected patients, and severe steatosis only for a non-3 hepatitis C virus genotype
por: Sagnelli, Caterina, et al.
Publicado: (2016)

Naturally occurring mutations associated with resistance to HCV NS5B polymerase and NS3 protease inhibitors in treatment-naïve patients with chronic hepatitis C
por: Costantino, Angela, et al.
Publicado: (2015)

Hepatitis D virus infection in a large cohort of immigrants in southern Italy: a multicenter, prospective study
por: Pisaturo, Mariantonietta, et al.
Publicado: (2022)

Correction: Hepatitis D virus infection in a large cohort of immigrants in southern Italy: a multicenter, prospective study
por: Pisaturo, Mariantonietta, et al.
Publicado: (2023)

Efficacy and safety of pegylated interferon α and ribavirin in patients monoinfected with HCV genotype 4
por: Kozielewicz, Dorota, et al.
Publicado: (2018)

Tolerability and efficacy of pegylated consensus interferon-α in the treatment of chronic hepatitis C
por: Ding, Yan-Hua, et al.
Publicado: (2017)

Epidemiological and clinical aspects of hepatitis B virus infection in Italy over the last 50 years
por: Sagnelli, Caterina, et al.
Publicado: (2022)

Cannabinoid Receptor 2-63 QQ Variant Is Associated with Persistently Normal Aminotransferase Serum Levels in Chronic Hepatitis C
por: Coppola, Nicola, et al.
Publicado: (2014)

Low-Dose Pegylated Interferon α-2b Plus Ribavirin for Elderly and/or Cirrhotic Patients with Genotype 2 Hepatitis C Virus
por: Tamai, Hideyuki, et al.
Publicado: (2016)

Resveratrol in Hepatitis C Patients Treated with Pegylated-Interferon-α-2b and Ribavirin Reduces Sleep Disturbance
por: Pennisi, Manuela, et al.
Publicado: (2017)

Autoimmune Hepatitis Triggered by Treatment With Pegylated Interferon α-2a and Ribavirin for Chronic Hepatitis C
por: Rathi, Chetan, et al.
Publicado: (2015)

Analysis of the Efficacy and Safety of PEGylated Interferon-α2b Treatment in Inactive Hepatitis B Surface Antigen Carriers
por: Huang, Yan, et al.
Publicado: (2021)

Cannabinoid receptor 2-63 RR variant is independently associated with severe necroinflammation in HIV/HCV coinfected patients
por: Sagnelli, Caterina, et al.
Publicado: (2017)

Prediction of response to pegylated-interferon-α and ribavirin therapy in Chinese patients infected with different hepatitis C virus genotype
por: Guo, Xiaoyan, et al.
Publicado: (2012)

Hepatitis B Virus (HBV) Reactivation Following Pharmacological Eradication of Hepatitis C Virus (HCV)
por: Pisaturo, Mariantonietta, et al.
Publicado: (2019)

Prevention of HBV Reactivation in Hemato-Oncologic Setting during COVID-19
por: Sagnelli, Caterina, et al.
Publicado: (2022)

Concurrent Autoimmune Hepatitis and Grave's Disease in Hepatitis C during Pegylated Interferon α-2a and Ribavirin Therapy
por: Trikudanathan, Guru V., et al.
Publicado: (2011)

Sex difference in the interaction of alcohol intake, hepatitis B virus, and hepatitis C virus on the risk of cirrhosis
por: Stroffolini, Tommaso, et al.
Publicado: (2017)

Pegylated Interferon α Therapy in Chronic Delta Hepatitis: A One-Center Experience
por: Bahcecioglu, Ibrahim Halil, et al.
Publicado: (2015)

Cutaneous side effects of combination therapy of pegylated interferon 2α and ribavirin
por: Raducan, Anca, et al.
Publicado: (2014)

Simeprevir-Based Triple Therapy with Reduced Doses of Pegylated Interferon α-2a Plus Ribavirin for Interferon Ineligible Patients with Genotype 1b Hepatitis C Virus
por: Tamai, Hideyuki, et al.
Publicado: (2017)

Effect of a Cooperation Strategy between Primary Care Physicians and Hospital Liver Units on HBV Care in Campania, Italy
por: Zampino, Rosa, et al.
Publicado: (2018)

Efficacy of 12-weeks velpatasvir plus sofosbuvir-based regimen in HCV-naive subjects with mild fibrosis: a meta-analysis
por: Mariantonietta, Pisaturo, et al.
Publicado: (2019)

Adverse Skin Reactions due to Ribavirin in Hepatitis C Combination Therapy with Pegylated Interferon-α(2a)
por: Shindo, Masahisa, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_ovrcvcpmaiackrootjfvco42cg